Fujirebio completes Innogenetics acquisition
Japanese diagnostics firm Fujirebio closes $112 million purchase of Belgian specialty diagnostics firm Innogenetics from Abbott Sept. 24. Abbott acquired Innogenetics in February as part of its $6.2 billion acquisition of Solvay Pharmaceuticals, but the divestiture was required to gain European Commission approval of the Solvay transaction. The Fujirebio pact was first announced in July. Both Fujirebio and Innogenetics develop diagnostics in areas such as infectious disease, genetic testing, transplantation and neuro-degeneration. Innogenetics also develops oncology tests, and has a special focus on molecular diagnostics and multiparameter testing
More from Archive
More from Medtech Insight
Back-to-back meetings at LSX? No time to attend the innovator showcase? Here is what you might have missed from medtech innovators at the LSX World Congress Europe on 29 April.
HistoSonics, which developed a noninvasive technology to destroy tumor cells, reports 90% local tumor control at 12-month follow-up in the #HOPE4Liver Trial. The Edison System, cleared by the US FDA in late 2023, is also being evaluated for kidney and pancreatic tumors. CEO Mike Blue said the medtech is financially secure but watching public markets as it considers an IPO.
Recognizing that the evidence it receives in applications for health technology assessments will increasingly be informed by artificial intelligence, the CDA-AMC has clarified its expectations for companies that use AI methods in the generation and/or reporting of evidence.